Популярное

Музыка Кино и Анимация Автомобили Животные Спорт Путешествия Игры Юмор

Интересные видео

2025 Сериалы Трейлеры Новости Как сделать Видеоуроки Diy своими руками

Топ запросов

смотреть а4 schoolboy runaway турецкий сериал смотреть мультфильмы эдисон
dTub
Скачать

ICH Q12 Guidance and Emerging Technology Program (11of16) Generic Drugs Forum 2020

Автор: U.S. Food and Drug Administration

Загружено: 2020-05-01

Просмотров: 4007

Описание:

Ashley Boam and Thomas O’Connor from CDER’s Office of Pharmaceutical Quality discuss ICH Q12 as it applies to generic drugs and CDER’s emerging technology program.

Learn more at https://www.fda.gov/drugs/news-events...


_______________________________
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.

Upcoming training and free continuing education credits: https://www.fda.gov/cdersbia

CDER SBIA 2020 Playlist:    • 2020 CDER Small Business and Industry Assi...  
LinkedIn:   / cder-small-business-and-industry-assistance  
Training resources: https://www.fda.gov/cderbsbialearn

Twitter:   / fda_drug_info  

CDER small business e-mail update subscription: https://updates.fda.gov/subscriptionm...

Email: [email protected]
Phone: (301) 796-6707 I (866) 405-5367

ICH Q12 Guidance and Emerging Technology Program (11of16) Generic Drugs Forum 2020

Поделиться в:

Доступные форматы для скачивания:

Скачать видео mp4

  • Информация по загрузке:

Скачать аудио mp3

Похожие видео

Common CMC (Quality) Issues and How to Avoid Them Part I (12of16) Generic Drugs Forum

Common CMC (Quality) Issues and How to Avoid Them Part I (12of16) Generic Drugs Forum

Medical Device Quality Management System Regulation Risk Management

Medical Device Quality Management System Regulation Risk Management

Learn About ClinicalTrials.gov Modernization and How to Provide Input – Mar. 6, 2020

Learn About ClinicalTrials.gov Modernization and How to Provide Input – Mar. 6, 2020

Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S03-2 – Q&A Discussion Panel

Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S03-2 – Q&A Discussion Panel

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

FDA Direct: Catching Up on Agency Reforms

FDA Direct: Catching Up on Agency Reforms

SEND for CBER, What You Need to Know

SEND for CBER, What You Need to Know

November 13, 2025: Pediatric Advisory Committee Meeting (PAC)

November 13, 2025: Pediatric Advisory Committee Meeting (PAC)

Medical Device Quality Management System Regulation Design and Development

Medical Device Quality Management System Regulation Design and Development

Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S07 – Q&A Discussion Panel

Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S07 – Q&A Discussion Panel

FDA Expert Panel on Testosterone Replacement Therapy for Men

FDA Expert Panel on Testosterone Replacement Therapy for Men

Investigational New Drug (IND) Submission: Content/Format and First 30 Days (5of14) REdI 2018

Investigational New Drug (IND) Submission: Content/Format and First 30 Days (5of14) REdI 2018

FDA Direct: Removing Black Box Warnings for HRT (Part 2/2)

FDA Direct: Removing Black Box Warnings for HRT (Part 2/2)

FDA-MHRA-HC 2024 Joint Symposium (Day 1)

FDA-MHRA-HC 2024 Joint Symposium (Day 1)

Tobacco Products Scientific Advisory Committee Meeting, October 7, 2025

Tobacco Products Scientific Advisory Committee Meeting, October 7, 2025

Process Validation and ICH Q7

Process Validation and ICH Q7

Public Meeting: Reauthorization of the Biosimilar User Fee Act

Public Meeting: Reauthorization of the Biosimilar User Fee Act

Initiating the Removal of the “Black Box Warning” on Hormone Replacement Therapy

Initiating the Removal of the “Black Box Warning” on Hormone Replacement Therapy

Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S06 - (PV): Regulatory Updates

Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S06 - (PV): Regulatory Updates

Regulatory Considerations for Impurity Qualification: ICH Q3A/Q3C/Q3D, RLD & MDD

Regulatory Considerations for Impurity Qualification: ICH Q3A/Q3C/Q3D, RLD & MDD

© 2025 dtub. Все права защищены.



  • Контакты
  • О нас
  • Политика конфиденциальности



Контакты для правообладателей: [email protected]